View This Report »
Get Industry Insights. Simply.
Talk to Amrita
+1 718 303 2019
As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...
How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...
Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...